

Gemini Stock Analysis Report

Based on the attached "Stock Detailed Analysis Report" for **DIVISLAB.NS** (Divi's Laboratories Ltd.), here is the positional trading assessment.

Note: The report date indicates **2026-01-10**. This analysis treats that date as "today/current."

Step 1: Audit the Data

- **Data Present:**
 - **Price Structure:** Daily, Weekly, and 15-minute candlestick charts with EMA overlays (20, 50, 200).
 - **Trend Indicators:** Moving Averages (EMA), Supertrend, MACD (Daily/Weekly).
 - **Momentum/Oscillators:** RSI (14), Relative Strength (RS) against benchmark ^CNXPHARMA.
 - **Volatility:** Bollinger Bands and ATR (Volatility Squeeze analysis).
 - **Fundamentals:** Snapshot of Revenue/EPS growth and Trendlyne scores (Durability, Valuation).
 - **Data Missing:**
 - **Volume Profile:** While daily volume bars are present, a Volume Profile (Volume at Price) is missing, which would help identify supply/demand nodes more precisely.
 - **Sector Breadth:** Detailed data on the broader Pharma sector performance (beyond just the RS comparison) is limited.
 - **Confidence Level: High.** The technical data is comprehensive, covering trend, momentum, volatility, and multiple timeframes, allowing for a robust technical decision.
-

Step 2: Analyze the Setup

- **Trend & Structure:**
 - **Primary Trend:** The stock is in a **Strong Uptrend**. Price (6616.50) is trading above the 20 EMA (6479), 50 EMA (6446), and 200 EMA (6243). The alignment (20>50>200) confirms bullish stacking.
 - **Correction & Bounce:** The stock recently corrected from highs near ~7000 to the 6400 level (testing the 50 EMA) and has successfully bounced. This is a classic "pullback to value" setup.
 - **Momentum Confluence:**
 - **Supertrend:** The Daily Supertrend flipped to **UPTREND (Buy)** on 2026-01-06 (4 days ago) with a support level at 6287.
 - **MACD:** A fresh bullish crossover (MACD line > Signal line) has occurred on the Daily chart, with momentum labeled as "Strengthening."
 - **RSI:** Current RSI is 60.82. This is the "sweet spot" for trend following-bullish but not yet overbought (>70).
 - **Relative Strength:** The stock has a 1-month RS score > 1.0 and is labeled an "Emerging Leader," indicating it is starting to outperform its sector index.
 - **Key Levels:**
 - **Support:** Immediate support is the 20 EMA (6479) and the critical 50 EMA floor (6446).
 - **Resistance:** The recent swing highs around 6900-7000 act as the primary supply zone.
-

Step 3: Formulate the Recommendation

Verdict: YES. The setup offers a high-probability entry. The stock has reset its momentum indicators via a pullback to the 50-day EMA and is now resuming its primary uptrend with confirmed buy signals from Supertrend and MACD.

Trade Plan:

Gemini Stock Analysis Report

- **Entry Price: INR 6616 - INR 6650** (Enter at Current Market Price).
 - *Rationale:* The stock has just confirmed a reversal from the 50 EMA support. Entering now captures the momentum leg up.
- **Stop Loss: INR 6430** (Closing Basis).
 - *Rationale:* This places the risk just below the 50-day EMA (6446) and the 20-day EMA. If the price closes below the 50 EMA, the intermediate trend is violated, and the thesis is invalid.
 - *Risk:* ~2.8%.
- **Take Profit: INR 7150 - INR 7300.**
 - *Rationale:*
 - **Target 1 (INR 7000):** A retest of the psychological round number and previous swing highs.
 - **Target 2 (INR 7300):** A breakout extension. Given the 1-month Relative Strength leadership, a breakout to new highs is statistically probable over a 1-4 month horizon.
 - *Upside:* ~8% - 10%.

Risk/Reward Ratio: Approximately 1:3 (Risking ~2.8% to make ~8-10%). This fits your criteria for a 5-15% upside with managed risk.

News & Analyst Targets

Current Date: **Saturday, January 10, 2026**

Here is the latest stock research and information for **Divi's Laboratories (DIVISLAB)** for the week ending January 10, 2026.

1) Latest News for DIVISLAB (Week of Jan 4 - Jan 10, 2026)

- **Strong Bullish Momentum & Derivative Surge:** On January 6, 2026, DIVISLAB witnessed a significant surge in Open Interest (OI) in its derivatives segment (up ~18-21%), accompanied by a stock price rally. This indicates strong long-buildup by traders expecting further upside.
- **Outperformance vs. Sector:** The stock hit an intraday high during the week, outperforming both the Nifty Pharma index and the broader Sensex, driven by fresh brokerage upgrades and sector rotation into defensive pharma stocks.
- **Trading Window Closed:** The company announced the closure of its trading window effective **January 1, 2026**, in preparation for the upcoming Q3 FY26 financial results. The window remains closed for insiders until 48 hours after the results are declared.
- **Jefferies & Citi Bullish Notes:** Major global brokerages Jefferies and Citi issued positive notes this week, citing 2026 as a potential "inflection year" for the company due to recovering API demand and strong custom synthesis (CS) visibility.

2) Brokerage Upgrades & Downgrades

- **Jefferies (Target Raise):** On **January 9, 2026**, Jefferies maintained its **BUY** rating and raised its price target to **INR 8,000** (from INR 7,850). They highlighted strong execution and a healthy growth outlook for the Contract Research, Development, and Manufacturing Organization (CRDMO) space.
- **Citi (Reiteration):** On **January 5, 2026**, Citi reiterated its **BUY** rating with a street-high target of **INR 9,140**. They termed 2026 as an "inflection year," expecting a recovery in the generics segment and strong catalysts from the GLP-1 (weight loss drug) and contrast media pipeline.
- **BP Wealth (New Pick):** The domestic firm listed DIVISLAB as one of its top "Techno-Funda" picks for January 2026, recommending a **BUY** with a target of **INR 7,210**.
- **Prabhudas Lilladhar (Technical Buy):** Issued a technical buy call for 2026 with a short-to-medium term

Gemini Stock Analysis Report

target of **INR 7,100**.

3) Indirect Impact & Other News

- **Sector Rotation into Pharma:** Market analysts have observed a shift of capital from high-valuation sectors into pharmaceuticals in early 2026. Experts like Sudip Bandyopadhyay have highlighted Divi's Labs as a top pick for 2026, citing improved global demand.
- **US FDA Clearance (Background):** The positive sentiment is underpinned by the clean chit (Zero Observations) received from the US FDA for its **Unit-I facility** in November 2025. This removes a major regulatory overhang that had previously concerned investors.
- **GLP-1 Opportunity:** Increasing analyst chatter surrounds Divi's role in the supply chain for GLP-1 agonists (weight-loss drugs), which is expected to be a major revenue driver in FY26-27.

4) Analyst Targets & Ratings (As of Jan 10, 2026)

Brokerage Firm	Rating	Target Price (INR)	Date / Note
Citi	BUY	9,140	Jan 05, 2026 (Top Pick)
Jefferies	BUY	8,000	Jan 09, 2026 (Target Raised)
BP Wealth	BUY	7,210	Jan 07, 2026 (Techno-Funda)
Prabhudas Lilladhar	BUY	7,100	Jan 01, 2026 (Technical Pick)
Motilal Oswal	Neutral	6,925	Nov 08, 2025 (Q2 Update)
Sharekhan	Buy	6,638*	Dec 11, 2025 (Review)
Kotak Inst. Equities	Sell	6,000	Nov 09, 2025 (Valuation concerns)
ICICI Securities	Sell	5,400	Nov 09, 2025 (Valuation concerns)

**Note: Targets from late 2025 are included for context where a fresh Jan 2026 note was not yet issued.*


Stock Detailed Analysis Report

DIVISLAB.NS

Current Price: ₹6616.50

Generated: 2026-01-10 10:19

DIVISLAB.NS - 3 Year Daily Price Chart



Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	Yes	19.61%	1.95%
Net Income	No	Yes	36.94%	-9.55%
ROE	No	Yes	24.15%	-16.61%
EPS	No	Yes	36.93%	-9.55%

Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	-5.49%	3.51%
Net Income	Yes	-17.67%	7.20%
ROE	Yes	18.95%	18.95%
EPS	Yes	15.62%	17.07%

DIVISLAB.NS - Relative Strength Analysis

== OVERVIEW ==:

Benchmark Index:	^CNXPHARMA
Sector:	Pharma
Classification:	Emerging Leader
RS Score:	50.3/100
:	

== RS RATIOS ==:

1M RS:	1.018 [Leader]
3M RS:	0.963 [Neutral]
6M RS:	0.947 [Neutral]
1Y RS:	1.172 [Leader]
:	

== TURNAROUND ANALYSIS ==:


Turnaround Status:	!! DETECTED !!
:	

SIGNAL CRITERIA::


✓ Emerging RS:	1M (1.018) > 3M (0.963)
✓ Medium-term Lagging:	6M=0.947 (≤ 1.0)
✓ Performance Improving:	3M (+7.9%) > 6M (-4.8%)

Relative Strength Analysis: DIVISLAB.NS vs ^CNXPHARMA
Classification: Emerging Leader


Price Performance Comparison (Normalized)



RS Ratio Trends (Multiple Timeframes)




RS Composite Score Timeline



DIVISLAB.NS - EMA Crossover Summary

EMA 20:	6479.30
EMA 50:	6446.46
EMA 200:	6243.51
Trend Status:	Strong Uptrend
Golden Cross Date:	2024-04-09 00:00:00+05:30
Golden Cross Price:	3764.60


DIVISLAB.NS EMA Crossover Analysis



DIVISLAB.NS - Bollinger Bands Summary

Current Price:	6616.50
Upper Band:	6666.90
Middle Band (SMA 20):	6449.43
Lower Band:	6231.95
%B:	0.8841
Band Width:	0.0674
Status:	Upper Half
Signal:	None


DIVISLAB.NS Bollinger Bands (20, 2) Analysis



DIVISLAB.NS - Supertrend Summary

Status:	UPTREND (Buy)
Supertrend Value:	6287.29
Signal Identified On:	2026-01-06

Supertrend Analysis for DIVISLAB.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




DIVISLAB.NS - MACD Summary

MACD Line:	37.59
Signal Line:	10.21
Histogram:	27.38
Trend:	Bullish
Momentum:	Strengthening
Signal:	None

DIVISLAB.NS Price






DIVISLAB.NS MACD (12, 26, 9)



DIVISLAB.NS - Volatility Squeeze Summary

BB Width:	0.0674
ATR:	123.7857
Total Signals:	31
Signal 1:	BB Squeeze at 2025-12-30 00:00:00+05:30 (Price: 6360.50)
Signal 2:	BB Squeeze at 2025-12-31 00:00:00+05:30 (Price: 6392.50)
Signal 3:	BB Squeeze at 2026-01-01 00:00:00+05:30 (Price: 6344.00)
Signal 4:	BB Squeeze at 2026-01-02 00:00:00+05:30 (Price: 6392.50)
Signal 5:	BB Squeeze at 2026-01-05 00:00:00+05:30 (Price: 6363.50)


DIVISLAB.NS - Volatility Squeeze Analysis



DIVISLAB.NS - RSI-Volume Summary

Current RSI:	60.82
Current Volume:	351042
Volume MA 20:	365813
Bullish Divergences:	1
Bearish Divergences:	1
Bullish Div 1:	Date: 2025-12-17 00:00:00+05:30, Price: 6293.00
Bearish Div 1:	Date: 2024-07-10 00:00:00+05:30, Price: 4587.77

DIVISLAB.NS RSI-Volume Divergence Analysis




Multi-Timeframe Supertrend Analysis

Timeframe	Status	Value	Last Price	Signal Date
1 Week	UPTREND (Buy)	6029.96	6616.5	2025-10-06
1 Day	UPTREND (Buy)	6287.29	6616.5	2026-01-06
15 Min	DOWNTREND (Sell)	6642.18	6607.5	2026-01-08

Multi-Timeframe MACD Analysis

Timeframe	Trend	Momentum	Signal
1 Week	Bearish	Weakening	No Signal
1 Day	Bullish	Strengthening	No Signal
15 Min	Bullish	Weakening	No Signal

DIVISLAB.NS - 1 Week (Candlestick + EMAs)




DIVISLAB.NS - 1 Day (Candlestick + EMAs)



DIVISLAB.NS - 15 Min (Candlestick + EMAs)



Trendlyne Snapshot - DIVISLAB_main



Trendlyne Snapshot - DIVISLAB_forecaster

MarketsSTARFOLIOAlertsF&O MF Reports ScreenersSubscribeSuperstarsPortfolioWatchlistInsider TradesResultsData DownloaderMore

Search Stock, IPO, MF

India

A

MARKETS / SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY / INDUSTRY: PHARMACEUTICALS / [DIVI'S LABORATORIES LTD.](#)

Divi's Laboratories Ltd. ⓘ

NSE: DIVISLAB | BSE: 532488

Expensive Star ⓘ

In 1 Starfolio Basket

6616.5016.00 (0.24%)
↑ 33.53% Gain from 52W Low

353.3K NSE+BSE Volume
NSE 09 Jan, 2026 3:31 PM (IST)

Watchlist

Portfolio

Alert

My Notes

TRADE STOCK

Overview

FORECASTER

STOCK REPORT

Buy Sell Zone

F&O

Financials

News

Reports

Technicals

Shareholding

Deals

Corporate Actions

Alerts

About

Divi's Laboratories - DIVISLAB - stock price prediction, stock forecast, target price, analyst ratings from 31 analysts

Divi's Laboratories has a share price target of Rs 6819, revenue growth forecast of 14.5%, and profit growth estimate of 18.2% for FY26, based on top 31 analyst calls.

Divi's Laboratories FORECASTER - Analyst Estimates ⓘ

[FORECASTER DASHBOARD →](#)

SHARE PRICE TARGET FORECAST12 MONTH ESTIMATE

LOW ESTIMATE: 4930
CURRENT PRICE: 6616.5
AVG. ESTIMATE: 6819.3
HIGH ESTIMATE: 9140

Legend: ● CURRENT PRICE ● AVG. ESTIMATE

HIT Divi's Laboratories's share price target is above the current price, with an upside of 3.1%

EPS FORECASTQUARTERANNUAL

Legend: ● ACTUAL EPS ● AVG. ESTIMATE

HIT Divi's Laboratories's EPS was higher than average estimate 2 times in past 3 years

CONSENSUS RECOMMENDATION31 ANALYST Recommendations

7	4	6	7	4	Aug '25
7	5	5	7	5	Sep '25
8	4	5	7	5	Oct '25
8	5	5	6	6	Nov '25
8	5	5	6	6	Dec '25
9	5	5	6	6	Jan '26

Legend: ● STRONG BUY ● BUY ● HOLD ● SELL ● STRONG SELL

HOLD

The consensus recommendation from 31 analysts for Divi's Laboratories is HOLD